Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Encouraging early detection and breaking the silence around men’s health
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Subscribe To Our Newsletter & Stay Updated